Chemical synthesis of Tegoprazan, a drug discovered by Pfizer and developed by RaQualia Pharma and CJ Healthcare for the treatment of gastroesophageal reflux disease (GERD). In 2018 its commercial use was approved in Korea. References: J. Med. Chem. 2020, 63, 19, 10652–10704. ...
Synthesis of Tegoprazan Starting with phenol 5, deprotonation of the phenol led to enhanced nucleophilicity, enabling selective Obenzylation. Bromination with NBS para to the aniline functionality afforded compound 6, an intermediate containing four appropriately placed functional groups in the heterocyclic ...
The present invention relates to methods for the synthesis of Tegoprazan and analogs thereof. 4-halo-2-methyl-1H-benzo[d]imidazole-6-carboxylate or 4-halo-2-methyl-1H-benzo[ d]imidazole-6-carboxylic acid amide compound is reacted with (S)-5,7-difluoro-3,4-dihydro-2H-chromen-4-ol to ...
Tegoprazan Usage And Synthesis Drug ApprovalTegoprazan was approved by the Ministry of Food and Drug Safety (MFDS) for marketing in July 2018 for the treatment of gastroesophageal reflux disease and erosive esophagitis. Tegoprazan was originally developed by Pfizer. In 2008, it was licensed to RaQual...
Process for synthesis of Tegoprazan analog , China, , , 合成路线:1 步 2948773-32-6 84% 942195-55-3 反应条件: 参考文献: Preparation of tegoprazan and its intermediate compound , China, , , 合成路线:1 步 2648486-32-0 72% 942195-55-3 反应条件: 参考文献: Preparation of ...
A Practical Green Synthesis of ( R )-5,7-difluorochroman-4-ol, a Key Intermediate of TegoprazanHaiping ZhouView further author informationHao SunView further author informationWenwen Yangwwyang@cqu.edu.cnView further author informationZongjie Gan...